Case Report: Recurrent coronary in-stent restenosis as the primary manifestation of non-criteria antiphospholipid syndrome confirmed by anti-phosphatidylserine/prothrombin IgM antibodies.
M, T., Y, L., Z, S., M, M., Y, F., & J, Y. (2026). Case Report: Recurrent coronary in-stent restenosis as the primary manifestation of non-criteria antiphospholipid syndrome confirmed by anti-phosphatidylserine/prothrombin IgM antibodies.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1852153
M T, Y L, Z S, M M, Y F, J Y. Case Report: Recurrent coronary in-stent restenosis as the primary manifestation of non-criteria antiphospholipid syndrome confirmed by anti-phosphatidylserine/prothrombin IgM antibodies.. Frontiers in immunology. 2026; doi: 10.3389/fimmu.2026.1852153
M T, Y L, Z S, et al. Case Report: Recurrent coronary in-stent restenosis as the primary manifestation of non-criteria antiphospholipid syndrome confirmed by anti-phosphatidylserine/prothrombin IgM antibodies.[J]. Frontiers in immunology. 2026. DOI: 10.3389/fimmu.2026.1852153.
@article{m2026,
author = {Tuo M and Li Y and Shi Z and Ma M and Feng Y and Yu J},
title = {Case Report: Recurrent coronary in-stent restenosis as the primary manifestation of non-criteria antiphospholipid syndrome confirmed by anti-phosphatidylserine/prothrombin IgM antibodies.},
journal = {Frontiers in immunology},
year = {2026},
doi = {10.3389/fimmu.2026.1852153},
note = {PMID: 42358967},
}
TY - JOUR AU - Tuo M AU - Li Y AU - Shi Z AU - Ma M AU - Feng Y AU - Yu J TI - Case Report: Recurrent coronary in-stent restenosis as the primary manifestation of non-criteria antiphospholipid syndrome confirmed by anti-phosphatidylserine/prothrombin IgM antibodies. T2 - Frontiers in immunology PY - 2026 DO - 10.3389/fimmu.2026.1852153 AN - PMID:42358967 ER -
BACKGROUND: A 47-year-old female with no traditional CAD risk factors developed recurrent in-stent restenosis (ISR) one year after LAD stenting. She had recurrent pregnancy loss, chronic urticaria, anemia, and proteinuria, with negative conventional antiphospholipid antibodies. CASE: After second stenting, aPS/PT IgM was elevated (51.65 U/mL), supporting the diagnosis of non-criteria APS. Thromboelastography (TEG) showed decreased R time, increased MA and CI, suggestive of a hypercoagulable state. Warfarin (INR 2-3) and hydroxychloroquine (200 mg bid) plus DAPT led to no chest pain recurrence and stent patency at 21-month follow-up. CONCLUSIONS: Recurrent ISR without traditional risk factors should raise suspicion for non-criteria APS. A moderately elevated aPS/PT IgM may serve as a diagnostic clue. Anticoagulation plus immunomodulation may help prevent further thrombotic events.